Search

News & Events

The Kids Research Institute Australia researchers have found close to 40 per cent of Aboriginal babies begin to develop middle ear infections between two and four months of age in a first of its kind study in metropolitan Perth.

News & Events

The Kids Research Institute Australia researchers have launched the Hip Hop 2 SToP video featuring school kids participating in their SToP Trial project designed to see, treat and prevent skin infections in WA’s Kimberley region.

News & Events

News headlines about the large number of life-threatening cases of the flu in Western Australia this winter have been hard to miss - find out what you can do to protect your family.

News & Events

Perth parents are underestimating the serious consequences of the flu, with only 19 per cent of children under five years of age currently immunized against the virus ahead of the peak winter flu season.

News & Events

New mothers in Perth are teaming up with researchers at The Kids Research Institute Australia in a global bid to develop the first vaccine to prevent Respiratory Syncytial Virus (RSV) disease.

Research

The Australian Technical Advisory Group on Immunisation and New Zealand Ministry of Health recommend all children aged ≥ 5 years receive either of the two mRNA COVID-19 vaccines: Comirnaty (Pfizer), available in both Australia and New Zealand, or Spikevax (Moderna), available in Australia only. Both vaccines are efficacious and safe in the general population, including children. Children and adolescents undergoing treatment for cancer and immunosuppressive therapy for non-malignant haematological conditions are particularly vulnerable, with an increased risk of severe or fatal COVID-19.

Research

Development of vaccines to prevent disease and death from Streptococcus pneumoniae, and nontypeable Haemophilus influenzae (NTHi), the main pathogens that cause otitis media, pneumonia, meningitis and sepsis, are a global priority.

Research

The proportion of births via cesarean section (CS) varies worldwide and in many countries exceeds WHO-recommended rates. Long-term health outcomes for children born by CS are poorly understood, but limited data suggest that CS is associated with increased infection-related hospitalisation. We investigated the relationship between mode of birth and childhood infection-related hospitalisation in high-income countries with varying CS rates.

Research

A multi-country randomized, placebo-controlled trial of the safety, immunogenicity and efficacy of respiratory syncytial virus (RSV) F-protein nanoparticle vaccine was undertaken in 4,636 pregnant women and their infants. RSV F-protein vaccine was safe and immunogenic in the pregnant women inducing anti-F IgG, palivizumab-competing antibodies and RSV neutralizing antibodies that were transferred to the fetus.

Research

Respiratory syncytial virus (RSV) is the most common cause of acute lower respiratory infection in young children. We previously estimated that in 2015, 33·1 million episodes of RSV-associated acute lower respiratory infection occurred in children aged 0-60 months, resulting in a total of 118 200 deaths worldwide.